Erschienen in:
29.05.2018 | Gastrointestinal Oncology
Future Treatment Strategy for Esophageal Cancer Based on Prediction of Systemic Recurrence: Significance of Pathologic Nodal Status After Neoadjuvant Chemotherapy
verfasst von:
Takushi Yasuda, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 8/2018
Einloggen, um Zugang zu erhalten
Excerpt
The main goals of neoadjuvant therapy are to increase the curative resection rate by downstaging the primary tumor and to improve postoperative survival by eliminating systemic micrometastases. Chemoradiotherapy (CRT), the mainstay of preoperative therapy for advanced esophageal cancer in Western countries, has dramatically improved local control by increasing the R0 resection rate. However, distant metastasis is common, and two recent randomized clinical studies comparing neoadjuvant CRT and neoadjuvant chemotherapy (NAC) failed to demonstrate a survival benefit of neoadjuvant CRT despite its favorable local control and R0 resection rates.
1,
2 …